Intervention not reported
Hb: final or change (g/dL) · adults and children with CKD
1 finding from 1 review
Intervention not reported
All‐cause mortality · people with liver metastases
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cancer mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
All adverse events and complications · people with liver metastases
The intervention led to higher all adverse events and complications; GRADE not reported.
1 finding from 1 review
Intervention not reported
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Recurrence of liver metastases Number of participants developing recurrences of liver metastases · people with liver metastases
The intervention showed no clear difference in recurrence of liver metastases Number of participants developing… (low certainty).
1 finding from 1 review
Intervention not reported
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Tumour response measures · people with liver metastases
1 finding from 1 review
50% or greater reduction in seizure frequency · people with focal epilepsy
Losigamone probably leads to higher 50% or greater reduction in seizure frequency compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with focal epilepsy
Losigamone probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · people with focal epilepsy
Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Dizziness · people with focal epilepsy
Losigamone probably leads to higher adverse event (dizziness) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in urinary GAG excretion from baseline · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Mean percentage change from baseline in FVC (% predicted) · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Mean change from baseline in 6MWT (metres) · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Infusion‐related reactions (number of participants with one or more reaction) · adults and children with mucopolysaccharidosis I
The intervention showed no clear difference in infusion‐related reactions (number of participants with one or more… (low certainty).
1 finding from 1 review
Intervention not reported
Antibody production: number of participants developing IgG antibodies · adults and children with mucopolysaccharidosis I
It is very uncertain whether the intervention changes antibody production: number of participants developing IgG antibodies (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life · adults and children with mucopolysaccharidosis I
1 finding from 1 review
Intervention not reported
Mortality: number of deaths · adults and children with mucopolysaccharidosis I
1 finding from 1 review
50% or greater reduction in seizure frequency · patients between 3 to 15 months of age with West syndrome
The review found no eligible studies for this question.
1 finding from 1 review